After MYC amplification, the next most common alterations in our analysis of the human BRCA1-deficient TNBCs were mutations and/or amplifications of PIK3CA (23/80 cases), indicating that activation of PI3K signaling is an important driver in this breast cancer subtype (Fig. 1a). This evidence concerns the gene PIK3CA and breast cancer.